Novo Nordisk Board Shake‑Up: Chairman Helge Lund and Six Members Step Down After Disagreement With Foundation
Novo Nordisk A/S (NYSE: NVO) announced today that Chairman Helge Lund and six other board...
Innovent and Takeda Forge $11.4 B Partnership on IBI363, IBI343 & IBI3001 ADC Therapies
Innovent Biologics, Inc. (HKG: 1801) today announced a landmark global strategic collaboration with Takeda Pharmaceutical...
Galapagos Announces Exit from Cell‑Therapy Business After Strategic Review
Galapagos NV (FRA: GXE) today disclosed that it has decided to wind down its cell‑therapy...
GFH375 Enters Phase Ib/II at Peking University: GenFleet Targets KRAS G12D
GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) today announced that the first patient has been enrolled...
Rani Therapeutics and Chugai Forge $1.085 Billion Collaboration Deal for Innovative Oral Therapeutic
Rani Therapeutics Holdings, Inc. today announced a comprehensive Collaboration and License Agreement with Japan’s Chugai...
BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4/6 IN BRIGHT‑3: Xuanzhu Biopharma Announces Interim Phase III Results at ESMO 2025
Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced that the interim analysis of the Phase III BRIGHT‑3...
Sichuan Biokin Secures NMPA Approval for BL‑M24D1 ADC, Targeting Relapsed Hematologic and Solid Tumors
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the National Medical Products Administration (NMPA)...
Huadong Medicine Secures FDA Approval for DR10624, First‑In‑Class Trispecific Agonist for Severe Hypertriglyceridemia
Huadong Medicine (SHE: 000963) announced that the Investigational New Drug (IND) application for DR10624 Injection,...
AstraZeneca & Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY‑Breast11 at ESMO 2025
AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) disclosed the Phase III DESTINY‑Breast11 results at...
Indetek Laboratory Secures NMPA Approval for IDT‑001 Gel, a Novel Film‑Forming Therapy for SSTIs
Indetek Laboratory announced that the National Medical Products Administration (NMPA) has formally accepted the New...
Fosun‑Henlius Announces 26.8‑Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC
Fosun Pharma (SHA: 600196) subsidiary Shanghai Henlius Biotech, Inc. (HKG: 2696) unveiled the final Phase III...
Novartis Announces Five‑Year NATALEE Results for Kisqali in HR+/HER2‑ Early Breast Cancer
Novartis (NYSE: NVS) presented the five‑year interim analysis of its pivotal Phase III NATALEE study at...
Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type 2 Diabetes
Novo Nordisk (NYSE: NVO) announced that the U.S. Food and Drug Administration (FDA) has granted...
Sino Biopharmaceutical Announces Breakthrough Phase III Results for Culmerciclib in HR+/HER2‑ Negative Breast Cancer
Sino Biopharmaceutical (HKG: 1177) today presented the interim analysis of its CULMINATE‑2 Phase III study at...
Sichuan Biokin Launches Phase III Trial of T‑Bren for HER2‑Mutant NSCLC
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today the enrollment of the first patient...
Anhui Anke Announces HuA21 Success in HER2‑Positive Gastric Cancer
Anhui Anke Biotechnology (Group) Co., Ltd. today released interim results from its Phase Ib/II study of...
Novartis Announces First‑In‑Class Phase III Data for Lutetium‑177 Vipivotide Tetraxetan in PSMA‑Positive Metastatic Hormone‑Sensitive Prostate Cancer
Novartis (NYSE: NVS) today disclosed the first data from its Phase III PSMAddition trial of lutetium‑177...
Boston Scientific Announces Nalu Medical Acquisition to Expand Chronic‑Pain Portfolio
Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement...
Accord Plasma Completes Acquisition of Prothya Biosolutions, Expanding European Plasma‑Derived Medicinal Product (PDMP) Capabilities
Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed...
Changchun High‑Tech Secures NMPA Approval for GenSci139 Bispecific ADC in Advanced Solid Tumors
Changchun High‑Tech (SHE: 000661) announced today that its wholly‑owned subsidiary, GenSci (GeneScience Pharmaceutical), has received...